EGFR and neoplasm: By co-modified with the CD133 + ligand (A15) and EGFR aptamer (CL4), CECP NPs achieved dual targeting effects of OSCs and OS cells, which reduced fourfold tumor spheres formation and the percentage of CD133 + cells, and obtained a 90% decrease of tumor volume in vivo [136].